CRVS · Corvus Pharmaceuticals Inc
United States · RS rating 26 · As of 2026-10-14
| Price | 9.38 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 7 / 10 / 83 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 28 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -25.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +63.2% |
| Market cap (USD) | $1.3B |